116 related articles for article (PubMed ID: 38266402)
1. UCHL-3 as a potential biomarker of ovarian cancer.
Yang Q; Peng X; Nian Z; Yuan S; Wang Z; Song Y; Shamsnur R; Wang H; Yi T
Gynecol Oncol; 2024 Mar; 182():156-167. PubMed ID: 38266402
[TBL] [Abstract][Full Text] [Related]
2. Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression.
Liu T; Fan MQ; Xie XX; Shu QP; Du XH; Qi LZ; Zhang XD; Zhang MH; Shan G; Du RL; Li SZ
J Transl Med; 2023 Sep; 21(1):656. PubMed ID: 37740194
[TBL] [Abstract][Full Text] [Related]
3. UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-κB pathway.
Zhang MH; Zhang HH; Du XH; Gao J; Li C; Shi HR; Li SZ
Oncogene; 2020 Jan; 39(2):322-333. PubMed ID: 31477831
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
5. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of UCHL3 inhibits esophageal squamous cell carcinoma progression by reducing CRY2 methylation.
Xue J; Yi J; Zhu X
Hum Cell; 2022 Mar; 35(2):528-541. PubMed ID: 35088238
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer.
Liu J; Liu Y; Yang C; Liu J; Hao J
Transl Oncol; 2023 Nov; 37():101762. PubMed ID: 37619523
[TBL] [Abstract][Full Text] [Related]
8. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer.
Liu Q; Yang X; Yin Y; Zhang H; Yin F; Guo P; Zhang X; Sun C; Li S; Han Y; Yang Z
Oxid Med Cell Longev; 2022; 2022():6575534. PubMed ID: 36561981
[TBL] [Abstract][Full Text] [Related]
9. A Novel Platinum Resistance-Related Immune Gene Signature for Overall Survival Prediction in Patients with Ovarian Cancer.
Zhou C; Ma J; Luo W; Hu J; Chen J; Liang S; He S
Biochem Genet; 2024 Feb; 62(1):112-124. PubMed ID: 37270714
[TBL] [Abstract][Full Text] [Related]
10. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract][Full Text] [Related]
11. GSK3β and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
Shan W; Peng W; Chen Y; Wang Y; Yu Q; Tian Y; Dou Y; Tu J; Huang X; Li X; Wang Z; Zhu Q; Chen J; Xia B
Oncogene; 2024 Jun; 43(25):1885-1899. PubMed ID: 38664501
[TBL] [Abstract][Full Text] [Related]
12. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
15. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
[TBL] [Abstract][Full Text] [Related]
16. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
17. A signature based on anoikis-related genes for the evaluation of prognosis, immunoinfiltration, mutation, and therapeutic response in ovarian cancer.
Duan Y; Xu X
Front Endocrinol (Lausanne); 2023; 14():1193622. PubMed ID: 37383389
[TBL] [Abstract][Full Text] [Related]
18. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
[TBL] [Abstract][Full Text] [Related]
19. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
20. LINC00665 knockdown confers sensitivity in irradiated non-small cell lung cancer cells through the miR-582-5p/UCHL3/AhR axis.
Xu LM; Yuan YJ; Yu H; Wang S; Wang P
J Transl Med; 2022 Aug; 20(1):350. PubMed ID: 35918714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
